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ABSTRACT
BACKGROUND: Malignant fibrous histiocytoma is most common soft tissue sarcoma occurring in late
adult life, most in the extremities and in the retroperitoneum, usually developing in deep fascia or skele-
tal muscle. Because of the aggressive nature of the tumor early and complete surgical removal is indi-
cated. The overall survival rate of patients with malignant fibrous histiocytoma ranges from 36% to 58%
at 5 years. Malignant fibrous histiocytoma in Vojvodina is still rare malignancy either in incidence or in
mortality in both sexes. The population of Vojvodina is about 2 100 000.
METHODS: We used a descriptive epidemiological method to analyze incidence and mortality from
malignant fibrous histiocytoma in Vojvodina. This study is based on the Cancer Registry data for the ten-
year period from 1993 to 2002.
RESULTS: During the observed period 37 cases of malignant fibrous histiocytoma were reported (19
men and 18 women). The average age of patients was 50 years. The body site distribution differed
between sexes and malignant fibrous histiocytoma was more common on the trunk (retroperitoneum) in
men and on the lower limbs in women. The average annual incidence rate for the observed period was
1.82 per 1 000 000 for both sexes. The incidence rate changed irregularly over the observed period with
the peak of 9 cases (4.55 per 1 000 000) in 2001. The overall linear trends of incidence and of mortal-
ity showed a slight increasing tendency in both sexes, but not significantly. Concerning mortality, the
similar patterns were noticed. The mortality rate was 0.83 per 1 000 000.
CONCLUSION: According to epidemiological data we obtained it can be concluded that Province of
Vojvodina is not a region with an important risk for malignant fibrous histiocytoma; however, the increase
of incidence appearing in both men and women should be taken into account very seriously in future.
KEY WORDS: Histiocytoma, Fibrous; Sarcoma; Epidemiology; Mortality; Incidence; Non MeSH Vojvodina
Institute of Oncology Sremska Kamenica, Serbia &
Montenegro, Address correspondence to: Dr. Borislava
Nikolin, Institute of Oncology Sremska Kamenica,
Instituttski put 4, 21204 Sremska Kamenica, Serbia &
Montenegro; The manuscript was received: 27.12.2004,
Provisionally accepted: 28.12.2004, Accepted for publica-
tion: 10.01.2005.
© 2005, Institute of Oncology  Sremska Kamenica, Serbia
&Montenegro
Arch Oncol 2005;13(1):16-7.
ORIGINAL ARTICLE
UDC:  616-006.8:616-036.22(497.113 Vojvodina)
INTRODUCTION 
Malignant fibrous histiocytoma (MFH), described by O’Brien and Stout in 1964, is the most
common soft tissue sarcoma occurring in late adult life. Uncertain histogenesis and numer-
ous subtypes make MFH a rather controversial entity. Researchers have postulated both
histiocytic and primitive mesenchymal cell theories of origin. In general, the tumor contains
both fibroblast like and histiocyte like cells in varying proportions, with spindled and round-
ed cells exhibiting a storiform arrangement. Five histological subtypes have been described
including (1) storiform/pleomorphic (most common), (2) myxoid, (3) giant cell, (4) inflam-
matory (usually retroperitoneal), and (5) angiomatoid (often located more superficially than
other varieties) (1,2).
The clinical stage of the tumor, which is defined by tumor grade, size, and presence of dis-
tant metastases, is the most important prognostic factor. Histological subtype and method
of surgical treatment are also important prognostic factors. The anatomic site and depth of
the primary tumor may also be of prognostic importance but this is controversial. Patients
with low-grade, intermediate-grade, and high-grade tumors have 10-year survival rates of
90%, 60%, and 20%, respectively. Patients with tumors smaller than 5 cm at presentation
have survival rates of 79%-82%. Patients with tumors of 5-10 cm have survival rates of
62%-68% and those with tumors larger than 10 cm have survival rates of 41%-51%. Distant
metastasis most commonly occurs to the lung (90%), bone (8%), and liver (1%). Rate of
metastasis varies with the histological subtype from 23% (myxoid) to 50% (giant cell).
Positive microscopic margins are associated with decreased disease-free survival while
resection with negative microscopic margins decreases the incidence of local recurrence;
however, these factors do not have a direct impact on outcome (2-4).
The overall survival rate of patients with MFH ranges from 36%-58% at 5 years; however,
patients with retroperitoneal tumors have an overall 5-year survival rate of 15%-20%. MFH
occurs more commonly in Caucasian patients than in patients of African or Asian descent.
Male-to-female ratio is approximately 2:1. The tumor occurs with a peak incidence in the
fifth and sixth decades but an age range of 10 to 90 years is reported. Although the tumor
is rare in children, the angiomatoid subtype is the most frequently occurring variety in
patients younger than 20 years (4-6). MFH occurs most commonly in the extremities (70%-
75%, with lower extremities accounting for 59% of cases), followed by the retroperitoneum.
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entation is an enlarging painless soft tissue mass in the thigh, typically 5-10 cm in diame-
ter. Two thirds of tumors are intramuscular. Retroperitoneal MFH usually presents with con-
stitutional symptoms, including fever, malaise, and weight loss. Early and complete surgi-
cal removal using wide or radical resection is indicated because of the aggressive nature of
the tumor. Biopsy is often necessary to make a diagnosis. Follow-up studies to exclude
tumor recurrence usually are performed using MRI (6,7). In order to find out the epidemio-
logical situation concerning MFH in Vojvodina, we made a retrospective analysis of the 10-
year period data.
MATERIALS AND METHODS
We used a descriptive epidemiological method to analyze the incidence and mortality from
MFH. The data covering a period from 01.01.1993 to 31.12.2002 were obtained from the
Cancer Registry of Vojvodina, Institute of oncology Sremska Kamenica (8). The Registry
covers the population of the whole territory of Province of Vojvodina with around 2 million
inhabitants. The rates were calculated per 1 000 000. The data on cancer reports are rou-
tinely collected through the registry network and processed by the registry staff according to
the IARC (International Agency for Research on Cancer, Lyon, France) recommendation (9).
RESULTS
MFH in Vojvodina is not among the ten most frequent malignancies neither in incidence nor
in mortality in both sexes. During the observed period 37 newly diagnosed cases of MFH
were reported, 19 in men and 18 in women, which gives the average annual incidence rate
of 1.82 per 1 000 000 for both sexes. The incidence rate changed irregularly over the
observed period with the highest peak of 9 cases (4.55 per 1 000 000) in 2001 (Figure 1).
The average age of patients was 50 years. The body site distribution differs between sexes
and MFH is more common in the trunk (retroperitoneum) in men and in the lower extremi-
ties in women. It should be said that the percentage of other and non-specified localization
is rather low, which is to be attributed to the high quality of the registration. The overall lin-
ear trends of incidence showed a slight increasing tendency (Figure 1).
Concerning mortality, the similar patterns were noticed. The mortality rate was 0.83/1 000
000 for both sexes. The overall time trend concerning mortality rates through the observed
period showed also increasing tendency (Figure 2).
DISCUSSION
The diagnosis of the MFH is based on specific cytomorphological characteristics and
immunocyto- and immunohistochemical staining. Literature data show that malignant
fibrous histiocytoma is rare disease of histiocytic and/or primitive mesenchymal cell in ori-
gin and account for about only 0.025% of all malignancies in adults but it is the most com-
mon soft tissue sarcoma occurring in late adult life. MFH is equally disease of men and
women. Most frequently, MFH metastasizes in lung, bone and liver (1,10-12). A significant
increasing number of cases among both male and female population in the Province of
Vojvodina has been registered. The overall linear trend of mortality is increasing. Increased
morbidity is followed by increased mortality, which suggests late diagnosis and lower qual-
ity of treatment. These results are quite in accordance with the worldwide figures
(8,9,13,14).
CONCLUSION
MFH in Vojvodina is still a rare malignancy either in incidence or in mortality in both sexes.
The prevention of MFH is impossible because of unknown etiology. By reason of this the
early detection is the most important factor for better prognosis. According to epidemio-
logical data we obtained it can be concluded that Province of Vojvodina is not a region with
an important risk for malignant fibrous histiocytoma; however, the increase of incidence
appearing in both men and women should be taken into account very seriously in future.
REFERENCES
1. Rosenberg AE. Malignant fibrous histiocytoma: past, present and future. Skeletal Radiol
2003;32:613-8.
2. Gibbs JF, Huang PP, Lee RJ, McGrath B, Brooks J, McKinley B et al. Malignant fibrous histiocy-
toma: an institutional review. Cancer Invest 2001;19(1):23-7.
3. Dimitrov DB. Cyclic patterns of cancer incidence in males by body site: data from the USA for the
period 1973-1989. J BUON 2000;5:81-4.
4. Sim FH, Frassica FJ, Frassica DA. Soft-tissue tumors: diagnosis, evaluation and management. J
Am Acad Orthop Surg 1994;2:202-11.
5. Kearney MM, Soule EH, Ivins JC. Malignant fibrous histiocytoma: a retrospective study of 167
cases. Cancer 1980;45(1):167-78.
6. Kransdorf MJ, Murphey MD. Imaging of Soft Tissue Tumors. Philadelphia: WB Saunders Co;
1997. p.192-209.
7. Pezzi CM, Rawlings MS Jr, Esgro JJ, Pollock RE, Romsdahl MM. Prognostic factors in 227
patients with malignant fibrous histiocytoma. Cancer 1992;69(8):2098-103.
8. Nepublikovani izve„taj Registra za maligne neoplazme Vojvodine. Institut za onkologiju Sremska
Kamenica, 1993-2002.
9. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in five continents, vol
VII. IARC Scientific publications No155. Lyon: IARC; 2002.
10. Resnick D. Diagnosis of Bone and Joint Disorders. 3rd ed. Philadelphia: WB Saunders Co; 1995.
p. 3964-4529.
11. Ros PR, Viamonte M Jr, Rywlin AM. Malignant fibrous histiocytoma: mesenchymal tumor of
ubiquitous origin. Am J Roentgenol 1984;142(4):753-9.
12. Peiper M, Zurakowski D, Knoefel WT, Izbicki JR. Malignant fibrous histiocytoma of the extremi-
ties and trunk: an institutional review. Surgery 2004;135:59-66.
13. Belal A, Kandil A, Allam A, Khafaga Y, El-Husseiny G, El-Enbaby A et al. Malignant fibrous histi-
ocytoma: a retrospective study of 109 cases. Am J Clin Oncol 2002;25:16-22.
14. Salo JC, Lewis JJ, Woodruff JM, Leung DH, Brennan MF. Malignant fibrous histiocytoma of the
extremity. Cancer 1999;85:1765-72.
Epidemiological characteristics of MFH
17
www.onk.ns.ac.yu/Archive    April 30, 2005
Figure 1. Incidence rates and trend of incidence of MFH in the Province of Vojvodina for the period
1993-2002
Figure 2. Mortality rates and trend of mortality of MFH in the Province of Vojvodina for the period
1993-2002